Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Group B Streptococcus Infection Treatment Market Revenue Growth On Track For A 8.6% CAGR Through 2030
Significant expansion has been observed in the group b streptococcus infection treatment market size in recent times. It will grow from $1.26 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this historical expansion include heightened recognition of neonatal infections, the broadening of prenatal care initiatives, the extensive application of beta-lactam antibiotics, the rise in hospital-based screening procedures, and the accessibility of microbiological testing services.
The market for group B streptococcus infection treatment is anticipated to experience substantial expansion over the coming years. This market is projected to reach $1.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. This projected growth during the forecast period is fueled by several factors, including the increasing advancement of GBS vaccines, greater acceptance of point-of-care diagnostic tools, a heightened focus on managing antimicrobial resistance, the expansion of molecular testing facilities, and a rising emphasis on proactive maternal healthcare. Key trends anticipated within this period involve the wider implementation of rapid molecular diagnostic testing, an intensified focus on prenatal GBS screening initiatives, the broader application of antibiotic stewardship protocols, an increase in pipeline therapies aimed at GBS prevention, and improved oversight of outcomes for mothers and newborns.
Get A Free Sample Report With In-Depth Market Insights:
Group B Streptococcus Infection Treatment Market Industry Drivers: What’s Behind The Revenue Growth?
The escalating healthcare expenditure is anticipated to foster the expansion of the group B streptococcus infection treatment market moving forward. This expenditure represents the entirety of financial resources dedicated to medical services, preventative care, medications, infrastructure, and related health activities, all aimed at maintaining or enhancing population health. Healthcare spending is on the rise primarily due to the increasing prevalence of chronic and infectious diseases, which, in turn, generates a sustained need for long-term treatment, advanced therapies, and continuous medical care. A surge in healthcare expenditure fortifies group B Streptococcus infection treatment by increasing investments in prenatal screening, clinical infrastructure, and vaccine research, thereby collectively improving early detection, prevention, and effective management of GBS infections in mothers and newborns. For instance, in April 2025, the Office for National Statistics, a UK-based government organization, reported that overall healthcare spending grew by 6.5% from 2023 to 2024, showing an acceleration compared to the 6.3% growth recorded in 2023. This indicates that rising healthcare expenditure is indeed a significant driver for the growth of the group B streptococcus infection treatment market.
Group B Streptococcus Infection Treatment Market Breakdown By Product Type And Application
The group b streptococcus infection treatment market covered in this report is segmented –
1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies
2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies
3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application
4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population
5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings
Subsegments:
1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics
2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy
3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies
#Group B Streptococcus Infection Treatment Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the group B streptococcus infection treatment market are concentrating on creating innovative solutions, such as polysaccharide conjugate vaccines, to reduce asymptomatic bacterial carriage. These immunizations involve chemically linking bacterial surface sugars to a carrier protein to enhance immune recognition and generate a robust, long-lasting protective response, particularly in infants and young children. For example, in September 2023, Omniose, a US-based biotechnology company, announced it had received a grant award of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine’s distinguishing feature is its objective to achieve high efficacy through a highly simplified manufacturing approach. Omniose’s platform employs synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, eliminating traditional chemical conjugation steps. This process ensures the preservation of 100% of sialic acid residues on each capsular polysaccharide, a factor demonstrated to be crucial for inducing strong functional antibody responses against specific GBS serotypes.
Group B Streptococcus Infection Treatment Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.
View The Full Group B Streptococcus Infection Treatment Market Report:
Group B Streptococcus Infection Treatment Market Geographic Spread And Regional Opportunities
North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the group b streptococcus infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model